MIMEDX GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.27 USD | +0.40% |
|
-0.32% | -28.51% |
| Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
| Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 824.9 | 976.3 | 670.5 | 315.5 | 1,020 | 925.3 | - | - |
| Enterprise Value (EV) 1 | 824.9 | 976.3 | 670.5 | 315.5 | 1,020 | 925.3 | 925.3 | 925.3 |
| P/E ratio | -31.6 x | -11.8 x | -40.3 x | -8.42 x | 23.7 x | 20.4 x | 16.1 x | 11.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 3.93 x | 2.59 x | 1.18 x | 3.17 x | 2.59 x | 2.29 x | 2.05 x |
| EV / Revenue | - | 3.93 x | 2.59 x | 1.18 x | 3.17 x | 2.59 x | 2.29 x | 2.05 x |
| EV / EBITDA | - | - | - | 80.6 x | 17.4 x | 12.6 x | 10.6 x | 8.75 x |
| EV / FCF | - | - | - | - | 41.2 x | 15.1 x | 12.9 x | - |
| FCF Yield | - | - | - | - | 2.43% | 6.64% | 7.73% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 108,828 | 107,521 | 111,010 | 113,500 | 116,358 | 147,583 | - | - |
| Reference price 2 | 7.580 | 9.080 | 6.040 | 2.780 | 8.770 | 6.270 | 6.270 | 6.270 |
| Announcement Date | 7/6/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 248.2 | 258.6 | 267.8 | 321.5 | 357.1 | 403.4 | 451.7 |
| EBITDA 1 | - | - | - | 3.914 | 58.48 | 73.33 | 87.4 | 105.7 |
| EBIT 1 | - | -45.4 | -5.035 | -24.97 | 55.06 | 52.98 | 66.22 | 84.62 |
| Operating Margin | - | -18.29% | -1.95% | -9.32% | 17.13% | 14.84% | 16.42% | 18.73% |
| Earnings before Tax (EBT) 1 | - | -61.54 | -10.04 | -29.99 | 30.63 | 53.04 | 73.32 | 84.12 |
| Net income 1 | -25.58 | -83.33 | -16.42 | -36.78 | 55.8 | 43.85 | 56.02 | 72.98 |
| Net margin | - | -33.57% | -6.35% | -13.73% | 17.36% | 12.28% | 13.89% | 16.15% |
| EPS 2 | -0.2400 | -0.7700 | -0.1500 | -0.3300 | 0.3700 | 0.3080 | 0.3900 | 0.5250 |
| Free Cash Flow 1 | - | - | - | - | 24.79 | 61.4 | 71.5 | - |
| FCF margin | - | - | - | - | 7.71% | 17.19% | 17.73% | - |
| FCF Conversion (EBITDA) | - | - | - | - | 42.39% | 83.73% | 81.81% | - |
| FCF Conversion (Net income) | - | - | - | - | 44.43% | 140.02% | 127.62% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/6/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 63.07 | 67.41 | 58.89 | 66.88 | 67.69 | 74.38 | 71.68 | 81.26 | 81.71 | 86.83 | 79.36 | 89 | 91.5 | 97.26 | 87.5 |
| EBITDA 1 | - | - | - | - | -0.724 | 7.317 | 5.543 | 14.1 | 17.62 | 21.22 | 13.67 | 18.5 | 19.03 | 21.73 | 15.5 |
| EBIT 1 | -1.075 | 3.301 | -9.3 | -9.636 | -7.103 | 1.072 | -3.381 | 2.788 | 10.82 | 20.41 | 8.301 | 13.6 | 14.27 | 16.81 | 10.2 |
| Operating Margin | -1.7% | 4.9% | -15.79% | -14.41% | -10.49% | 1.44% | -4.72% | 3.43% | 13.24% | 23.51% | 10.46% | 15.28% | 15.59% | 17.29% | 11.66% |
| Earnings before Tax (EBT) 1 | -2.038 | 2.107 | -10.43 | -10.81 | -8.373 | -0.381 | -4.932 | 1.126 | 9.125 | 13.91 | 7.568 | 13.63 | 14.59 | 17.25 | 10.2 |
| Net income 1 | -3.913 | 0.618 | -12.08 | -12.5 | -10.1 | -2.11 | -6.667 | -0.528 | 6.761 | 44.83 | 6.303 | 11.29 | 11.86 | 14.4 | 7.6 |
| Net margin | -6.2% | 0.92% | -20.5% | -18.68% | -14.92% | -2.84% | -9.3% | -0.65% | 8.27% | 51.63% | 7.94% | 12.69% | 12.96% | 14.8% | 8.69% |
| EPS 2 | -0.0400 | 0.0100 | -0.1100 | -0.1100 | -0.0900 | -0.0200 | -0.0600 | - | 0.0600 | 0.3200 | 0.0440 | 0.0780 | 0.0820 | 0.0980 | 0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/28/22 | 5/3/22 | 8/2/22 | 11/2/22 | 2/28/23 | 5/2/23 | 8/1/23 | 10/30/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 24.8 | 61.4 | 71.5 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 1.51 | 1.99 | 2.9 | 3.3 | - |
| Capex / Sales | - | - | - | 0.57% | 0.62% | 0.81% | 0.82% | - |
| Announcement Date | 7/6/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.27
USD
Average target price
12.44
USD
Spread / Average Target
+98.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.51% | 925M | |
| -20.60% | 128M | |
| -7.82% | 67.46M | |
| +14.87% | 61.68M | |
| +6.64% | 60.58M | |
| +0.60% | 51.45M |
- Stock Market
- Equities
- MDXG Stock
- Financials MiMedx Group, Inc.
